• News
  • SAN DIEGO
  • Finance

U.S. Stocks Rise as Drug Makers Rally Amid Optimism Over Economy

June 20 (Bloomberg) -- U.S. stocks rose, sending the Dow Jones Industrial Average to a record, as drug makers rallied on merger activity and investors speculated economic growth will accelerate.

Health-care companies in the Standard & Poor’s 500 Index jumped 0.8 percent amid a takeover offer for Shire Plc. CarMax Inc. jumped 17 percent after quarterly results topped forecasts as increased customer traffic boosted vehicle sales. Oracle Corp. slid 5.7 percent after reporting profit and sales that fell short of analysts’ estimates.

The Standard & Poor’s 500 Index climbed 0.2 percent to 1,963.67 at 11:16 a.m. in New York. The gauge has climbed for six consecutive days, its longest winning streak since April. The Dow added 51.38 points, or 0.3 percent, to a record 16,972.84. The Nasdaq Composite Index increased 0.1 percent.

“This is an energy bunny sort of market that wants to keep marching higher and for a good reason,” Terry Sandven, chief equity strategist at Minneapolis-based U.S. Bank Wealth Management, which oversees $120 billion, said by phone. “The U.S. economy is showing varying signs of improvement. Earnings are rising, interest rates are low and inflation is elevated, but not at extremes. That’s a favorable environment for equities to march higher.”

Trading in S&P 500 companies was more than 75 percent above the 30-day average for this time of day. Stock trading may be subject to unexpected swings because of a quarterly event known as quadruple witching, when futures and options contracts on indexes and individual stocks expire.

Yellen Comments

Equities rallied this week after Fed Chair Janet Yellen said accommodative monetary policy, rising property and equity prices and the improving global economy should lead to above- trend growth. Yellen emphasized the need to put more Americans back to work and downplayed concerns about asset-price bubbles and incipient inflation.

The S&P 500 is trading at 16.6 times the projected earnings of its members, up from 15.5 times at the beginning of the year.

The gauge is heading toward an advance of 1.4 percent for the week. It is up 8.2 percent since a low on April 11 as data showed the economy is recovering from the impact of extreme weather earlier this year.

Reports yesterday showed the Fed Bank of Philadelphia’s factory index unexpectedly climbed in June and a Labor Department release showed claims for unemployment benefits dropped more than expected.

Recouping Losses

The best U.S. stocks this month are ones that just a few months ago were the biggest losers. Netflix Inc., Tesla Motors Inc. and TripAdvisor Inc. have rallied more than 16 percent in the past four weeks, recouping most of the losses from a rout during March and April. The Nasdaq Composite Index reached a 14- year high this week and the Russell 2000 Index is 2 percent from a record. Both fell at least 8 percent earlier in 2014.

Six out of 10 main industries in the S&P 500 advanced today. Energy and health-care companies had the best performance, while technology and utility shares slumped.

Drug companies rallied amid merger activity. AbbVie Inc. is considering raising its takeover bid for Shire Plc a fourth time after the European drugmaker rejected its latest offer for about $46.5 billion, said two people with knowledge of the matter.

Merck, Lilly

Cross-border deals are accelerating as U.S. companies seek lower taxes and ways to spend almost $2 trillion protected from U.S. taxes in cash abroad. Merck & Co. increased 1.5 percent. Eli Lilly & Co. jumped 2.7 percent, Alexion Pharmaceuticals rose 2.8 percent and Amgen Inc. climbed 2.2 percent.

CarMax added 17 percent to $52.86. Demand for autos has risen with an improving job market, more housing starts and low interest rates. That drove the annualized pace for new light- vehicles sales, adjusted for seasonal trends, to 16.8 million last month, the fastest rate since February 2007, according to Autodata Corp.

AutoNation Inc. rallied 2.6 percent to $57.96.

Oracle slid 5.7 percent to $40.08. Fiscal fourth-quarter profit and sales fell short of estimates as Salesforce.com Inc. and other cloud-computing rivals lure customers away.

Darden Restaurants Inc. fell 3.2 percent to $47.95. The seafood and Italian restaurant chain owner reported fiscal fourth-quarter profit and revenue that trailed analysts’ estimates as sales at Oliver Garden continued to slump.

Merrimack Pharmaceuticals Inc. lost 8.4 percent to $7.23 after the biotechnology company said it has reached an agreement with French drugmaker Sanofi to regain the right to develop and commercialize its cancer treatment MM-121.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!